Dyslipidemia in Special Ethnic Populations

Pu, Jia; Romanelli, Robert J.; Zhao, Beinan; Azar, Kristen M.J.; Hastings, Katherine; Nimbal, Vani; Fortmann, Stephen P.; Palaniappan, Latha

doi:10.1016/j.ecl.2015.09.013

Cited by 20 publications

(11 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28][29][30] More recent guidelines in China are consistent with this approach. [28][29][30] More recent guidelines in China are consistent with this approach.…”

Section: Introductionmentioning

confidence: 89%

Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre‐specified analysis of the Chinese population from the BERSON clinical trial

Chen

Yuan

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim The aim of this study was to evaluate the efficacy and safety of evolocumab with background atorvastatin in Chinese patients with type 2 diabetes mellitus (T2DM) and hyperlipidaemia or mixed dyslipidaemia. Materials and methods This is a pre‐specified analysis of patients in the BERSON study (http://clinicaltrials.gov, NCT02662569) in China. Patients initiated background atorvastatin 20 mg/d, after which they were randomized 2:2:1:1 to evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM) or to placebo Q2W or QM. Co‐primary endpoints were percentage change in LDL cholesterol (LDL‐C) from baseline to week 12 and from baseline to the mean of weeks 10 and 12. Additional endpoints included atherogenic lipids, glycaemic measures and adverse events (AEs). Results Among 453 patients randomized in China, 451 received at least one dose of study drug (evolocumab or placebo). Evolocumab significantly reduced LDL‐C compared with placebo at week 12 (Q2W, −85.0%; QM, −74.8%) and at the mean of weeks 10 and 12 (Q2W, −80.4%; QM, −81.0%) (adjusted P < 0.0001 for all) when administered with background atorvastatin. Non‐HDL‐C, ApoB100, total cholesterol, Lp(a), triglycerides, HDL‐C and VLDL‐C significantly improved with evolocumab vs placebo. No new safety findings were observed with evolocumab. The incidence of diabetes AEs was higher with evolocumab compared with placebo. There were no differences over time between evolocumab and placebo in measures of glycaemic control. Conclusions In patients in China with T2DM and hyperlipidaemia or mixed dyslipidaemia receiving background atorvastatin, evolocumab significantly reduced LDL‐C and other atherogenic lipids, was well tolerated, and had no notable impact on glycaemic measures.

show abstract

“…[28][29][30] More recent guidelines in China are consistent with this approach. [28][29][30] More recent guidelines in China are consistent with this approach.…”

Section: Introductionmentioning

confidence: 89%

Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre‐specified analysis of the Chinese population from the BERSON clinical trial

Chen

Yuan

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…The pooled effect of R219K on HDLC levels in Asian populations was signi cantly higher than in Caucasian populations (SMD Asian vSMD Caucasian = -0.24 v -0.04, Q = 5.20, df = 1, P = 0.023). Many reports also mentioned the racial/ethnic difference in lipid levels and related diseases [114,115]. Thus, investigating the observed racial difference would help determine whether this phenomenon results from the real in uence of R219K polymorphism on HDLC level or from the distinctive allele distribution of R219K in different ethnicities.…”

Section: Discussionmentioning

confidence: 99%

Association Between ABCA1 (R219K) Polymorphism and Lipid Profiles: A Meta-Analysis

Shi¹,

Tian²,

Wu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Conflicting evidence was found about the relationship between lipid profiles and R219K in adenosine triphosphate-binding cassette exporter A1 (ABCA1) gene. A meta-analysis was conducted to assess the effect of R219K on lipid level. Methods Multi-database literature search was performed in accordance with PRISMA guidelines. The effect of each study was expressed by standard mean difference (SMD) and 95% confidence interval and pooled by meta-analysis in a random-effects model. Sub-group and meta-regression analyses were also conducted to explore potential heterogeneity sources. Results Overall pooled effect showed that individuals with RR genotype had significantly lower HDLC level (SMD = -0.17 mmol/L, 95% CI: -0.22 ~ -0.12, z = -6.39, P < 0.001) than those with K allele. However, this effect mainly presented in Asians (SMD = -0.24 mmol/L, 95% CI: -0.32 ~ -0.17, z = 6.60, P < 0.001) rather than Caucasian populations, and the difference was significant (Q = 5.20, df = 1, P = 0.02). The relationship between R219K polymorphism and LDLC, TC, and TG levels was not determined. Conclusions R219K polymorphism in the ABCA1 gene was associated with HDLC level in Asian populations in the present meta-analysis. This correlation was not substantially affected by the age, gender or health condition of individuals.

show abstract

“…There are several genetic variants associated with altered statin metabolism. Singlenucleotide polymorphisms in the genes that encode the organic anion-transporting polypeptide (OATP) 1B1 (521 T > C), which regulates hepatic uptake of statins, and the adenosine triphosphate-binding cassette G2 (ABCG2) transporter (421C > A), which regulates hepatic efflux, have been reported [125][126][127]. Plasma exposure to rosuvastatin and its metabolites was significantly higher in Chinese, Malay, and Asian-Indian subjects compared with white subjects living in Singapore [128].…”

Section: Statin Metabolismmentioning

confidence: 99%

Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease and ESRD, and Minority Groups

Brar¹,

Santana²,

Salifu³

et al. 2019

Dyslipidemia

View full text Add to dashboard Cite

This chapter discusses the management of dyslipidemia in special patient populations: the elderly, woman and pregnancy, renal disease, human immunodeficiency virus (HIV), and different racial/ethnic groups. In the elderly, dyslipidemia is often underdiagnosed and undertreated. Consideration for potential atherosclerotic risk-reduction benefits, risk of adverse effects, drug-drug interactions, and patient preferences should precede the initiation of statin therapy. Data on pregnant women are lacking and need future research. Dyslipidemia and its effects on the cardiovascular system in chronic kidney disease (CKD), end-stage renal disease (ESRD), and HIV are dynamic and multimodal. These conditions are states of chronic inflammation, where it is difficult to associate quantities of cholesterol types with outcomes. Among all racial groups, Asian Indians, Filipinos, and Hispanics are at a higher risk for dyslipidemia. Genetic differences in statin metabolism may explain this racial/ethnic difference.

show abstract

Dyslipidemia in Special Ethnic Populations

Cited by 20 publications

References 66 publications

Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre‐specified analysis of the Chinese population from the BERSON clinical trial

Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre‐specified analysis of the Chinese population from the BERSON clinical trial

Association Between ABCA1 (R219K) Polymorphism and Lipid Profiles: A Meta-Analysis

Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease and ESRD, and Minority Groups

Contact Info

Product

Resources

About